It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Medical information request
Medical information request

MSNEXT

MSNEXT is a study designed to characterize the demographic and clinical profile of RRMS patients (N=804) receiving fingolimod in Spain, and to evaluate drug effectiveness and safety in clinical practice, with a minimum follow-up of 12 months

Incidence of AEs and SAEs1

MSNEXT table-v
Link to article DoI
border
Abbreviations
AE, adverse event; RRMS, relapsing-remitting multiple sclerosis; SAE, serious adverse event
Reference
1. Barrero F, et al. PLoS ONE 2020;15(4):e0230846.
 
* Indication wording varies in different countries. The current website is a global information resource. Local Prescribing Information/ Summary of Product Characteristics approved by individual country’s regulatory authority is the primary source of information for the indication of fingolimod in the individual country.